UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Annals of oncology, 2022-01, Vol.33 (1), p.114-116

2022

Volltextzugriff (PDF)

Clinical Practice Guidelines of the Russian Scientific Liver Society, Russian Gastroenterological Association, Russian Association of Endocrinologists, Russian Association of Gerontologists and Geriatricians and National Society for Preventive Cardiology on Diagnosis and Treatment of Non-Alcoholic Liver Disease

Rossiĭskiĭ zhurnal gastroėnterologii, gepatologii, koloproktologii, 2022-12, Vol.32 (4), p.104-140

2022

Volltextzugriff (PDF)

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma

Medicinskij sovet, 2022-06 (9), p.157-162

2022

Volltextzugriff (PDF)

Second-line treatment of hepatocellular carcinoma: from theory to practical issues

Medicinskij sovet, 2019-12 (19), p.30-36

2019

Volltextzugriff (PDF)

Immunotherapy for hepatocellular carcinoma in liver transplant patients (Literature review)

Vestnik medit͡s︡inskogo instituta Reaviz, 2023-09, Vol.13 (4), p.162-168

2023

Volltextzugriff (PDF)

Рembrolizumab as second line therapy for hepatocellular patient

Medicinskij sovet, 2021-12 (20), p.150-154

2021

Volltextzugriff (PDF)

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Medicinskij sovet, 2021-08 (9), p.18-24

2021

Volltextzugriff (PDF)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

Bezopasnostʹ i risk farmakoterapii (Online), 2023-06, Vol.11 (2), p.215-230

2023

Volltextzugriff (PDF)

Resolution on the results of Advisory Board “Searching the effective methods of testing and treating patients with NSCLC caused by NTRK gene fusions

Medicinskij sovet, 2022-06 (9), p.50-56

2022

Volltextzugriff (PDF)

Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel

Rossiĭskiĭ zhurnal gastroėnterologii, gepatologii, koloproktologii, 2023-02, Vol.32 (5), p.16-23

2023

Volltextzugriff (PDF)

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

Medicinskij sovet, 2020-12 (20), p.194-198

2020

Volltextzugriff (PDF)

Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment

Medicinskij sovet, 2020-07 (9), p.190-195

2020

Volltextzugriff (PDF)

Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

Annals of oncology, 2019-07, Vol.30, p.iv135-iv136

2019

Volltextzugriff (PDF)

Immunotherapy for hepatocellular cancer: beginning and future perspectives

Medicinskij sovet, 2019-06 (10), p.15-21

2019

Volltextzugriff (PDF)

Neoadjuvant therapy bridging patients with hepatocellular cancer waiting for liver transplant

Medicinskij sovet, 2021-12 (20), p.110-116

2021

Volltextzugriff (PDF)

Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping

Medicinskij sovet, 2021-08 (9), p.154-159

2021

Volltextzugriff (PDF)

Prognostic value of the proportion of the sclerosing component in fibrolamellar liver carcinoma

Medicinskij sovet, 2021-12 (20), p.94-100

2021

Volltextzugriff (PDF)

Fibrolamellar liver cancer: the modern concept

Medicinskij sovet, 2020-12 (20), p.134-142

2020

Volltextzugriff (PDF)

Oncological care for the patients with hepatocellular carcinoma in COVID-19 pandemic

Medicinskij sovet, 2020-07 (9), p.226-231

2020

Volltextzugriff (PDF)

Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine

Hereditary cancer in clinical practice, 2021-01, Vol.19 (1), p.2-2, Article 2

2021

Volltextzugriff (PDF)

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Medicinskij sovet, 2019-12 (19), p.16-21

2019

Volltextzugriff (PDF)

Stereotactic hypofractive radiotherapy in the treatment of patients with lung cancer

Medicinskij sovet, 2020-12 (20), p.150-156

2020

Volltextzugriff (PDF)

PHARMACOLOGICAL THERAPY OF HEPATOCELLULAR CANCER PRACTICAL ISSUES AND SOLUTIONS

Medicinskij sovet, 2017-11 (14), p.11-23

2017

Volltextzugriff (PDF)

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

Medicinskij sovet, 2020-07 (9), p.16-24

2020

Volltextzugriff (PDF)

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

The New England journal of medicine, 2020-05, Vol.382 (20), p.1894-1905

2020

Volltextzugriff (PDF)

1 – 25 von 163

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(64)

Publikationsform

Artikel
(161)
Tagungsberichte
(2)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

VP10-2021: Cabozantinib (C) plus atezolizumab (A) versus sorafenib (S) as first-line systemic treatment for advanced hepatocellular carcinoma (aHCC): Results from the randomized phase III COSMIC-312 trial

Nivolumab with Ipilimumab in the treatment of refractory hepatocellular carcinoma

Second-line treatment of hepatocellular carcinoma: from theory to practical issues

Immunotherapy for hepatocellular carcinoma in liver transplant patients (Literature review)

Рembrolizumab as second line therapy for hepatocellular patient

Five-year results of nivolumab for the treatment of non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)

Resolution on the results of Advisory Board “Searching the effective methods of testing and treating patients with NSCLC caused by NTRK gene fusions

Screening and Early Diagnosis of Hepatocellular Cancer and Optimization of Diagnostic Imaging Techniques: A Review and Conclusion of the Expert Panel

Clinical case of use of osimertinib in a patient with disseminated EGFR-mutated non-small cell lung cancer in the first-line therapy

Firsthand experience of chemoradiotherapy in patients with localized small cell lung cancer. Retrospective assessment

Pembrolizumab (Pembro) therapy vs best supportive care (BSC) in advanced hepatocellular carcinoma (HCC): KEYNOTE-240

Immunotherapy for hepatocellular cancer: beginning and future perspectives

Neoadjuvant therapy bridging patients with hepatocellular cancer waiting for liver transplant

Experience of treatment of a patient with non-small cell lung cancer with met exon 14 skipping

Prognostic value of the proportion of the sclerosing component in fibrolamellar liver carcinoma

Fibrolamellar liver cancer: the modern concept

Oncological care for the patients with hepatocellular carcinoma in COVID-19 pandemic

Revisiting multiple erroneous genetic testing results and clinical misinterpretations in a patient with Li-Fraumeni syndrome: lessons for translational medicine

Three-year results of application of nivolumab in patients with non-small cell lung cancer in clinical practice of the N.N. Blokhin Russian Cancer Research Center

Stereotactic hypofractive radiotherapy in the treatment of patients with lung cancer

PHARMACOLOGICAL THERAPY OF HEPATOCELLULAR CANCER PRACTICAL ISSUES AND SOLUTIONS

Immuno-related endocrinopathy in patients treated with immune checkpoint inhibitors

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Suchergebnisse filtern